Search

Your search keyword '"Pfister, Stefan M."' showing total 252 results

Search Constraints

Start Over You searched for: Author "Pfister, Stefan M." Remove constraint Author: "Pfister, Stefan M." Journal neuro-oncology Remove constraint Journal: neuro-oncology
252 results on '"Pfister, Stefan M."'

Search Results

1. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary

2. A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFR.

3. Risk factors for domain-specific neurocognitive outcome in pediatric survivors of a brain tumor in the posterior fossa – Results of the HIT 2000 trial

4. Treatment response as surrogate to predict risk for disease progression in pediatric medulloblastoma with persistent magnetic resonance imaging lesions after first-line treatment.

5. Pediatric low-grade gliomas: next biologically driven steps.

6. Gliomatosis cerebri in children: A poor prognostic phenotype of diffuse gliomas with a distinct molecular profile

7. Pediatric high-grade glioma: biologically and clinically in need of new thinking.

9. EANO - EURACAN - SNO Guidelines on circumscribed astrocytic gliomas, glioneuronal, and neuronal tumors

10. Mapping pediatric brain tumors to their origins in the developing cerebellum

11. Clinical outcome of pediatric medulloblastoma patients with Li–Fraumeni syndrome

13. LOGGIC Core BioClinical Data Bank: Added clinical value of RNA-Seq in an international molecular diagnostic registry for pediatric low-grade glioma patients

14. Risk prediction in early childhood sonic hedgehog medulloblastoma treated with radiation-avoiding chemotherapy: Evidence for more than 2 subgroups

15. BH3 mimetics targeting BCL-XL impact the senescent compartment of pilocytic astrocytoma

16. The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models

17. PATH-08. DNA methylation profiling improves routine diagnostics of paediatric CNS tumours: a prospective population-based study

18. MEDB-38. Significance of CSF cytology and neurologic deterioration in relapsed medulloblastomas in the German HIT-REZ-97/-2005 Studies and the HIT-REZ-Register

19. PATH-13. Methylation analysis in the diagnosis of pediatric CNS tumors; a single center experience

20. HGG-50. Specific sensitivity of pediatric high-grade glioma with ATRX inactivation to PARP inhibitor combinations

21. HGG-61.Landscape of cancer predisposition in pediatric high-grade glioma

22. MEDB-37. Chemotherapy response prediction by molecular risk factors in metastatic childhood medulloblastoma

23. OTHR-32. The Pediatric Targeted Therapy 2.0 registry: robust molecular diagnostics for precision oncology

24. LGG-06. Selumetinib in pediatric patients with non-neurofibromatosis type 1-associated, non-optic pathway (OPG) and non-pilocytic recurrent/progressive low-grade glioma harboring BRAFV600E mutation or BRAF-KIAA1549 fusion: a multicenter prospective Pediatric Brain Tumor Consortium (PBTC) Phase 2 trial

25. HGG-16. Final analysis of the HIT-HGG-2007 trial (ISRCTN19852453): Significant survival benefit for pontine and non-pontine pediatric high-grade gliomas in comparison to previous HIT-GBM-C/-D trials.

26. LGG-25. The first-in-class ERK inhibitor ulixertinib (BVD-523) shows activity in MAPK-driven pediatric low-grade glioma models as single agent and in combination with MEK inhibitors or senolytics

27. LGG-27. Molecular implications of mitogen-activated protein kinase pathway inhibition by the MEK inhibitor trametinib in BRAF-fusion-driven pediatric pilocytic astrocytoma

28. ATRT-08. SMARCB1- and SMARCA4-deficient malignant brain tumors with complex copy number alterations andTP53 mutations may represent the first clinical manifestation of Li-Fraumeni syndrome

29. DIPG-19. FOXR2 is an oncogenic driver across pediatric and adult cancers

30. RARE-15. Astroblastoma, MN1 altered comprises two molecularly and clinically distinct subgroups defined by the fusion partners BEND2 and CXXC5

31. HGG-49. Gliomatosis cerebri in children: A collaborative report from the European Society for Pediatric Oncology (SIOPE)

33. LGG-18. Inhibition of Bcl-xL targets the senescent compartment of pilocytic astrocytoma

34. IMMU-04. Transcriptional analysis reveals distinct microenvironmental subgroups across pediatric nervous system tumors

35. MEDB-41. Identifying a subgroup of patients with early childhood sonic hedgehog-activated medulloblastoma with unfavorable prognosis after treatment with radiation-sparing regimens including intraventricular methotrexate

37. MODL-07. DNA methylation-based biobank of murine models for pediatric tumors

39. LGG-17. Preventing recurrence: targeting molecular mechanisms driving tumor growth rebound after MAPKi withdrawal in pediatric low-grade glioma

41. LGG-14. LOGGIC (Low Grade Glioma in Children) Core BioClinical Data Bank: Establishment and added clinical value of an international molecular diagnostic registry for pediatric low-grade glioma patients

42. INSP-15. ITCC-P4: A sustainable platform of molecularly well-characterized PDX models of pediatric cancers for high throughputin vivo testing

43. MODL-04. Drug screening in Disorders with Abnormal DNA Damage Response/Repair (DADDR) andin vivo validation

45. EPEN-08. Single-cell transcriptome analysis defines a tumor-supportive microenvironment and tumor-stroma crosstalk in pediatric ependymoma and medulloblastoma.

46. MEDB-14. Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome

47. THER-01. Precision brain tumor therapy by AAV-mediated oncogene editing

48. IMMU-11. Evaluation of CAR-T cells targeting CD276 in medulloblastoma

49. RARE-12. Pineoblastoma of children and young adults in a national population: An analysis of the HIT-MED study cohort

Catalog

Books, media, physical & digital resources